The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis

Abstract

Liver fibrosis is a common link in the transformation of acute and chronic liver diseases to cirrhosis. It is of great clinical significance to study the factors associated with the induction of liver fibrosis and elucidate the method of reversal. Peroxisome proliferator-activated receptors (PPARs) are a class of nuclear transcription factors that can be activated by peroxisome proliferators. PPARs play an important role in fibrosis of various organs, especially the liver, by regulating downstream targeted pathways, such as TGF-β, MAPKs, and NF-κB p65. In recent years, the development and screening of PPAR-γ ligands have become a focus of research. The PPAR-γ ligands include synthetic hypolipidemic and antidiabetic drugs. In addition, microRNAs, lncRNAs, circRNAs and nano new drugs have attracted research interest. In this paper, the research progress of PPAR-γ in the pathogenesis and treatment of liver fibrosis was discussed based on the relevant literature in recent years.

Keywords:

• liver fibrosis
• PPAR-γ
• HSCs
• agonists

Acknowledgments

This work was supported by China Foundation for Hepatitis Prevention and Control WBN liver Disease Research Fund (grant No. CFHPC2019031), and the Shanghai Sailing Program (grant No. 20YF1443300).

Disclosure

The authors report no conflicts of interest in this work.